axitinib
Sponsor Pfizer INC · listed as PFE
READOUT
Phase 3
Confidence: medium
Source: clinicaltrials
axitinib is a clinical-stage drug asset sponsored by Pfizer INC, listed as PFE. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Dec 31, 2026 (day precision, medium confidence), tied to trial NCT05059522. The asset is in Phase 3 and currently active not recruiting, studied in Advanced Malignancies. It appears across 2 tracked trials in the CSA sample.
Next catalyst
Event typeREADOUT
Expected date2026-12-31
As disclosedDec 31, 2026
Date precisionday
Confidencemedium
Trial & sponsor
Trial (NCT)NCT05059522
PhasePHASE3
StatusACTIVE_NOT_RECRUITING
Lead sponsorPfizer
Listed asPFE
Condition(s)Advanced Malignancies; NSCLC; Ovarian Cancer; Urothelial Cancer; Solid Tumors
!
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This is one row of the free CSA sample. The full snapshot carries 2,103 forward catalysts across 139 listed sponsors.
Get the full dataset — $499 → More PFE catalysts